Skip to main content
Authored Items
New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives in Multiple Myeloma, ASCO Highlights
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Web Exclusives in AACR Highlights
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
Wayne Kuznar
Web Exclusives in Cholangiocarcinoma
Neoantigens Are Effective Targets for Developing Cancer Vaccines
Wayne Kuznar
Web Exclusives
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with CLL
Wayne Kuznar
JHOP - March 2019 Vol 9, No 1 in ASH Highlights, Leukemia
Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma
Wayne Kuznar
Web Exclusives in Immunotherapy, Renal-Cell Carcinoma
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
Web Exclusives in Lynch Syndrome
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
Web Exclusives in Immunotherapy
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
Web Exclusives in FDA Oncology Update
Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Web Exclusives in ASH Highlights
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Wayne Kuznar
Web Exclusives
Last modified: June 10, 2010